As the blockbuster model comes under threat, Genzyme's highly diversified approach begins to look smart. Plenty of larger companies likely envy Genzyme's specialist expertise, tight customer relationships and long-standing embrace of external R&D. It's up to CEO Henri Termeer to prove that these strengths warrant an independent future for Genzyme.
Melanie Senior
Like most Big Biotechs, Genzyme Corp. has been associated with one major drug—its Gaucher’s disease treatment imiglucerase (Cerezyme). With sales...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Aneesh Karatt-Vellatt is leading the charge to redefine how ion channels and G protein-coupled receptors (GPCRs) are targeted with antibody therapies, one of the most notoriously challenging classes of drug targets.
In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.
New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.
